The effectiveness of treatment in non-small-cell lung cancer (NSCLC) depends on the accurate determination of the genomic status of the tumour. For this reason, molecular analyses to detect tumour genomic aberrations have become standard of care in patients with advanced disease, and now also in patients with early disease.
Please join us for this unique opportunity to take a deep dive into the Lung Cancer Molecular Diagnostic Pathway, with a specific focus on tumour molecular testing. We will cover how to ensure optimal tissue sampling and the tissue requirements for molecular testing as well as discussing the successes, challenges and applications of ctDNA in lung cancer diagnosis.
The day will include a unique opportunity to hear from several leading clinical scientists from two London Genomic Laboratory Hubs. They will discuss the key assays used in the genomic laboratory, and will provide a useful guide to the interpretation of an NGS report for the clinician, as well as offering an exclusive insider view on the benefits and challenges of the recent changes to genomic testing services across the UK.
Finally the information learnt will be brought together in a number of illustrated case presentations and discussions led by two lung cancer medical oncologists.
Who should attend?
Junior to intermediate level clinicians as well as consultants in oncology and respiratory medicine. Other healthcare professionals within the lung cancer multidisciplinary team.
Please go to the Robens Suite on the 29th Floor of Tower Wing, Guy’s Hospital for registration and welcome coffee
09:30 – 09:35
Welcome and agenda
Dr Eleni Karapanagiotou, Guy’s and St Thomas’ NHS Foundation Trust
Dr Debra Josephs, Guy’s and St Thomas’ NHS Foundation Trust
09:35 – 10:00
Treating NSCLC; Setting the scene
Dr Eleni Karapanagiotou, Guy’s and St Thomas’ NHS Foundation Trust
Dr Debra Josephs, Guy’s and St Thomas’ NHS Foundation Trust
10:00 – 10:50
Tissue Sampling EBUS vs IR-guided procedures in NSCLC
Professor George Santis and IR Consultant (TBC)
10:50 – 11:00
Coffee break
11:00 – 11:30
Tissue Requirements for diagnosis
NSCLC Histological subtypes, IHC and genomic tests, challenges and pitfalls
Martina Munonyara, Consultant Pathologist, Guy’s and St Thomas’ NHS Foundation Trust
11:30 – 11:55
Genomic testing -Inside the Lab. Understanding the assay choices
Nicola Foot, Service Lead for Cancer Genetics, Consultant Clinical Scientist, Guy’s and St Thomas’ NHS Foundation Trust
11:55 – 12:20
Circulating tumour DNA- successes, challenges and applications
Gareth Gerrard, Clinical Scientist and Scientific Lead for Cancer Genomics (South East Genomic Laboratory Hub), Guy’s and St Thomas’ NHS Foundation Trust
12:20 – 12:45
Interpretation of an NGS report for the clinician
Amy Roe, Operational Lead for Cancer Genetics (South East Genomic Laboratory Hub), Guy’s and St Thomas’ NHS Foundation Trust
12:20 – 12:45
Lunch
Janssen Sponsor Symposia
14:00 – 14:30
UK Genomic Testing Landscape with focus on Lung Cancer
Changes to the system, the benefits and remaining gaps and challenges
Dr Philip Bennett, Principal Clinical Scientist and Service Lead
Sarah Cannon Molecular Diagnostics
14:30 – 15:30
Does tumour molecular profiling really matter?
Case presentations with imaging. Delegates will debate and discuss appropriate treatment options
Dr Eleni Karapanagiotou, Guy’s and St Thomas’ NHS Foundation Trust
Dr Debra Josephs, Guy’s and St Thomas’ NHS Foundation Trust
Bayer plc aims to develop products that improve people’s quality of life. We concentrate on the research and development of innovative drugs and novel therapeutic approaches to prioritise targets and pathways with the potential to impact not just the treatment of common cancers, but rarer cancers as well.
UK healthcare professionals and other relevant UK decision makers can register here to subscribe to electronic communications about Bayer’s products, services and events: https://pro.bayer.co.uk/
Visit https://oncology.bayer.co.uk/ for more information.
PP-PF-ONC-GB-0179
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world.
In the UK, we employ approximately 1,500 people to serve healthcare needs across the whole of the UK, as well as supporting the global operations of Novartis. Since 2014, Novartis has invested over £200 million in R&D and is a leading sponsor of clinical trials, in the UK. For more information, please visit www.novartis.co.uk
This website uses cookies to improve your experience while you navigate through the website. The cookies that are categorised as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies.
Some cookies are essential for you to be able to experience the full functionality of our site. For example, they allow us to maintain user sessions and prevent security threats. They do not collect or store any personal information.
Cookie
Duration
Description
cookielawinfo-checkbox-analytics
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional
11 months
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy
11 months
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
wp-settings-1, wp-settings-time-1
WordPress uses this cookie to customise your view of admin interface, and possibly also the main site interface.
X-Mapping-fjhppofk
This cookie is used for load balancing purposes. The cookie does not store any personally identifiable data.
These are the cookies that help certain non-essential functionalities on our website. For example, analytics tools to measure how you use the website so we can improve it based on user needs. This could include anonymous information of how you got to the site, the pages you visit and how long you spend on each page.
Cookie
Duration
Description
_ga
This cookie is installed by Google Analytics. This cookie is used to distinguish unique users by assigning a randomly generated number as a client identifier. It is included in each page request and used to calculate visitor, session and campaign data for the site's analytics reports.
_gat_gtag_[property_id]
This cookie is also part of Google Analytics and is used to limit requests (throttle request rate).
_gid
This cookie is installed by Google Analytics. The cookie is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected includes the number of visitors, the source where they have come from and the pages visited.
